Skip to content
MarketScale
Demo
‹ Back to IndustriesSciences

Geothermal Exploration ‘Takes Flight’ with FTG

Geothermal energy is a hot topic in the energy space. However, locating geothermal energy requires complex surveys. There are many options, but innovative companies are taking to the skies. Discussing how these surveys work with FTG (Full Tensor Gradiometry), Bell Geospace Lead Geophysicist Alan Morgan joined host Hilary Kennedy on the company’s podcast. Morgan is…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · EnergyFtgGeothermalGradiometry
Share

Key takeaways

01

Geothermal energy is a hot topic in the energy space.

02

However, locating geothermal energy requires complex surveys.

03

There are many options, but innovative companies are taking to the skies.

Geothermal energy is a hot topic in the energy space. However, locating geothermal energy requires complex surveys. There are many options, but innovative companies are taking to the skies.

Discussing how these surveys work with FTG (Full Tensor Gradiometry), Bell Geospace Lead Geophysicist Alan Morgan joined host Hilary Kennedy on the company’s podcast. Morgan is an expert in gradiometry exploration and data acquisition.

First, Morgan explained how FTG works. “FTG detects density contrasts. By flying FTG surveys, what we are doing is detecting faults and constraining the “cup” that holds the heated fluids’’.The difference with FTG compared to standard gravity surveys is that it measures the rate of change of gravity in all directions. “FTG offers a 3D measurement,” Morgan added. Essentially this is a better resolution image and provides more details on the shape, depth, size… etc

Using FTG for gradiometry exploration and data acquisition supports seismic, especially in the near subsurface– up to 500m where seismic data is difficult to constrain. Additionally, FTG is routinely utilized to perform quantitative 2D modelling along seismic profiles to evaluate sedimentary density as a function of porosity.

Morgan shared several specific surveys that had anomalies. Anomalies are something he’s always interested in digging into, and, on occasion, he’s able to go to the location.

There were anomalies in one survey in Indonesia, which, upon investigation, related to weathering and sand texture differences. Being on-site helped him collect the most accurate data to answer the questions.

Morgan also spoke about silica and geothermal activity. “Silica is an indicator that there is excess heat in the system. In south Texas, some wells record over 60° Celsius water temperatures. There is potential to take advantage of these temperatures.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512